Therapeutic Response

TSC2 oncogenic variants status confers therapeutic sensitivity to Everolimus in patients with Subependymal Giant Cell Astrocytoma.

Statements

Source and description
Afinitor (everolimus) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.